Amanta Healthcare IPO

81.96x

subscribed

Amanta Healthcare IPO

Pharmaceuticals & Drugs
listed
₹14,280Min. investment
  1. Pre-apply
    29 Aug
  2. Bid start
    1 Sep
  3. Bid end
    3 Sep
  4. Allotment
    4 Sep
  5. Release of funds
    8 Sep
  6. Demat transfer
    8 Sep
  7. Listing
    9 Sep

About Amanta Healthcare Limited

SectorPharmaceuticals & Drugs
Price range₹120 – ₹126
IPO type
Regular
Lot size119 shares
Issue size₹126Cr
Red Herring Prospectus
Read
Market Cap
₹489.25CrLower than sector avg
RevenueApr 2024 - Mar 2025
₹274.71CrLower than sector avg
Growth rate3Y CAGR
1.97%

Amanta Healthcare Limited IPO Overview

Amanta Healthcare Limited IPO date

Amanta Healthcare Limited IPO will open for subscription on September 1, 2025, and the closing date for the IPO is September 3, 2025. After this, investors are expected to be updated about the allotment status on September 04, 2025.

Investors who have been allotted shares can expect them to be credited to their demat account on September 08, 2025. The shares will be listed on the NSE and the BSE on Monday, September 09, 2025.

Amanta Healthcare Limited IPO price band

The IPO includes a fresh issue of shares. The IPO price band has been set between ₹120 to ₹126 per share. Interested investors can choose a price within this band to apply for the IPO.

The IPO is a book-building issue, comprising a fresh issue of ₹126 crore only.

Amanta Healthcare Limited's IPO listing price will be determined on September 8, 2025. The listing price is the price at which a company’s shares debut on the stock exchanges.

Amanta Healthcare Limited IPO lot size

Amanta Healthcare Limited IPO details have been declared. The minimum lot size for an application is 119 shares, and the investor would have to apply for a minimum of 1 lot. Meanwhile, the IPO issue size is approximately ₹ 126 crore.

Checklist

Quality analysis
Revenue growth
Company valuation
Earnings expansion
Risk analysis
Debt to Equity ratio
Promoter holdings
Shares pledged
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Compare

Companies in this sector
Sun Pharmaceutical Industries LtdSun Pharmaceutical Industries Ltd
Divi's Laboratories LtdDivi's Laboratories Ltd
Cipla LtdCipla Ltd
Revenue
Higher revenue means strong sales and good market demand
This IPO
₹274.71Cr
This sector
₹1,331.47Cr
Compare with companies
PAT
Higher PAT means strong profitability and efficient cost management
This IPO
₹10.5Cr
This sector
₹193.4Cr
Compare with companies
Market cap
Higher market cap means strong confidence but may suggest overvaluation
This IPO
₹489.25Cr
This sector
₹10,914.84Cr
Compare with companies
P/E ratio
Lower ratio usually means stock is undervalued
This IPO
33.96
This sector
60.87
Compare with companies
D/E ratio
Lower ratio usually means fewer liabilities
This IPO
2.02
This sector
0.43
Compare with companies

Objectives

Funding of Capex
79.47%
General corporate purposes
20.60%

Strength and Weakness

Well-diversified product portfolio

The company offers products across 6 therapeutic segments - fluid therapy, formulations, diluents, ophthalmic, respiratory care and irrigation solutions with 47 products registered. The wide container offerings, ranging from 2 ml to 1000 ml, with closure systems such as nipple head, twist-off, leur-lock and screw types, further strengthen its diversified product base.

Strong manufacturing capabilities

The facility, spread over 66,852 sq. metres in Kheda, Gujarat, houses 4 LVP lines (2 ABFS and 2 ISBM) and 3 SVP lines (2 ABFS and 1 conventional). With the ability to manufacture sterile liquids from 2 ml to 1000 ml at a single location, it holds ISO and WHO-GMP certifications, ensuring quality compliance.

Wide sales and distribution network

The company has a domestic network of 320 distributors/stockists supported by a 96-member sales team, supplying to hospitals and nursing homes. International registrations across 120 jurisdictions strengthen its global reach.

Technology-enabled operations

The company employs advanced manufacturing technologies such as Form Fill Seal (FFS), producing ~8 bottles every 15 seconds with nitrogen purging, and Injection Stretch-Blow Moulding (ISBM) with automated terminal sterilisation at 109°C, ensuring sterile, high-quality output. On the commercial side, pharma cloud and sales force automation enable efficient demand planning, forecasting, cost control, and risk management.

About Amanta Healthcare Limited

Incorporated in 1994, Amanta Healthcare Limited is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products, including parenteral products, packed in plastic containers using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technology. The company manufactures large-volume parenterals (LVPs) and small-volume parenterals (SVPs) across 6 therapeutic segments, along with medical devices.
The company operates through 3 strategic business units: national sales, international sales, and product partnering with various foreign and Indian pharmaceutical companies. The company markets over 45 products under its own brands in the Indian market through a network of over 320 distributors and stockists. The international sales contributed 32.68% of total revenue in FY25 compared to 29.31% in FY24.
It operates a manufacturing facility spread over 66,852 sq m in Gujarat, India. The facility includes four large-volume parenterals (LVP) manufacturing lines and three operational small-volume Parenterals (SVP) manufacturing lines. The company offers a comprehensive range of products, including fluid therapy (IV fluid), formulations, diluents, ophthalmic solutions, respiratory care and irrigation solutions in the therapeutic segment, plus products like irrigation, first-aid solutions, and eye lubricants in the medical device segment. As of 22 Aug 2025, the company has a portfolio of 47 products registered across 120 international jurisdictions.
As of March 31, 2025, the company achieved overall capacity utilisation of 96%, with LVP at 91%, SVP at 99%, and SteriPort at 91% utilisation rates. Total installed capacity stands at 33.19 crore units with actual production of 31.83 crore units.
Global health expenditure was US$9.8T in 2022, approximately 9.9% of world GDP. India’s current health expenditure (CHE) is only 3.3% of GDP, well below developed peers, suggesting a long runway as policy focus post-COVID sustains spending. Per-capita CHE in India is just US$273, again highlighting headroom. Health’s share in India’s private final consumption expenditure has risen steadily to 5.2% in FY24. The National Health Policy targets lifting government health outlay to 2.5% of GDP; pharma accounts for a relatively high share of CHE in India (21% in 2020), indicating structural demand for cost-effective therapies and essential hospital consumables.
Amanta focuses on sterile liquids (LVPs/SVPs) across fluid therapy, diluents, ophthalmic, respiratory and irrigation, directly exposed to rising hospitalisations and procedure volumes as health spending climbs from a low base. Two-port IV fluids enjoy materially higher ceiling prices than single-port, e.g., 500 ml glucose 5% at ₹82.27 vs ₹37.98. The company sells two-port under SteriPort, allowing it to skew to higher-realisation SKUs while remaining within price controls.
Now, Amanta Healthcare Ltd is launching its initial public offering (IPO), which is a complete fresh issue worth ₹126 crore. Its shares will be listed on the NSE and BSE.

IPO Subscription Status

Date
QIB
NII
Retail
Total
01-Sep-25
0.03 times (X)
5.82 times (X)
6.81 times (X)
4.67 times (X)
02-Sep-25
0.29X
36.22X
23.51X
19.72X
03-Sep-25
30.08X
207.3X
53.92X
81.96X

Latest News on IPO

news logo
Ahmedabad-based pharmaceutical company Amanta Healthcare, has filed a draft red herring prospectus with SEBI to raise funds through an IPO of 1.25 crore equity shares, aiming to set up a new manufacturing line and purchase equipment for another line, with remaining funds for general corporate purposes.
news logo
Amanta Healthcare IPO: The initial share sale is exclusively a fresh issuance of 1,00,00,000 shares. There is no offer for sale component.

2 min read

news logo
Amanta Healthcare IPO is solely a fresh issuance of one crore shares, without an offer for sale (OFS) component. Since there is no OFS, the money raised will be retained by the company.

2 min read

news logo
Amanta Healthcare IPO: The initial share sale is exclusively a fresh issuance of one crore shares amounting to ₹126 crore. The price range is fixed at ₹120 to ₹126 per share.

3 min read

news logo
Amanta Healthcare IPO day 3: The ₹126 crore initial public offering is a completely fresh issuance of one crore equity shares without an offer for sale (OFS) component.

3 min read

news logo
Amanta Healthcare share price: The ₹126 crore initial public offering is purely a fresh issuance of 1 crore equity shares with no offer for sale (OFS) component. It had a price range of ₹120 to ₹126 per share.

2 min read

Frequently asked questions

How to invest in the IPO?

Investors can apply for the IPO through their Demat account via the stock exchange or through their broker.

What is the issue size of Amanta Healthcare IPO ?

The issue size of the Amanta Healthcare IPO is 126 Cr.

What is 'pre-apply' for Amanta Healthcare IPO ?

Pre-applying for an IPO allows you to submit your application before the official subscription period begins.

Which exchanges will Amanta Healthcare IPO shares list on?

The IPO shares will typically list on major stock exchanges such as the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), as specified in the IPO prospectus.